WSI CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,836 KRW | -0.65% |
|
-4.82% | -17.11% |
| 2023 | WSI Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 2021 | WSI Co., Ltd. announced that it has received KRW 18.3 billion in funding | CI |
| Sales 2022 | 27.13B 19.72M | Sales 2023 | 30.88B 22.45M | Capitalization | 66.51B 48.35M |
|---|---|---|---|---|---|
| Net income 2022 | 4.37B 3.18M | Net income 2023 | 2.88B 2.09M | EV / Sales 2022 | 1.39 x |
| Net cash position 2022 | 18.58B 13.51M | Net Debt 2023 | 2.82B 2.05M | EV / Sales 2023 | 2.25 x |
| P/E ratio 2022 |
15.8
x | P/E ratio 2023 |
29.1
x | Employees | 27 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 30.25% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.65% | ||
| 1 week | -4.82% | ||
| Current month | -7.04% | ||
| 1 month | -8.20% | ||
| 3 months | -13.40% | ||
| 6 months | +0.60% | ||
| Current year | -17.11% |
1 week
1 811.00
1 934.00
1 month
1 811.002 030.00
Current year
1 811.002 645.00
1 year
1 750.002 645.00
3 years
1 505.003 560.00
5 years
1 505.005 800.00
10 years
1 505.005 800.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jung-Sub Park
CEO | Chief Executive Officer | 58 | 20-11-16 |
Sang-Yeob Lee
AUD | Comptroller/Controller/Auditor | 49 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jung-Sub Park
CEO | Chief Executive Officer | 58 | 20-11-16 |
Dae-Heum Park
BRD | Director/Board Member | 63 | - |
Yoon-Seok Lee
BRD | Director/Board Member | 47 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 1,836 | -0.65% | 31,261 |
| 24-04-16 | 1,848 | -2.79% | 73,928 |
| 24-04-15 | 1,901 | -0.78% | 20,728 |
| 24-04-12 | 1,916 | -0.16% | 53,530 |
| 24-04-11 | 1,919 | -0.52% | 16,976 |
End-of-day quote Korea S.E., April 16, 2024
More quotes
WSI Co Ltd, formerly IBKS No.10 Special Purpose Acquisition Co, is a Korea-based company mainly engaged in the sale of pharmaceuticals and medical devices. The Company mainly distributes the topical hemostatic agent Flosils. In addition, the Company supplies endoscopes related to spinal surgery, anti-adhesion agents, and bone hemostatic agents.
Sector
Pharmaceuticals
Calendar
2024-05-23
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -17.11% | 39.87M | |
| +13.59% | 69.43B | |
| +5.67% | 26.07B | |
| +5.02% | 7.98B | |
| -1.71% | 7.79B | |
| -27.52% | 7.13B | |
| +0.18% | 4.52B | |
| +21.54% | 4.39B | |
| -2.45% | 3.98B | |
| -4.54% | 3.82B |
- Stock Market
- Equities
- A299170 Stock
